EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative products based on the NexACT® drug delivery technology, today confirmed that previously unpublished clinical data on Femprox, the Company’s topical treatment for female sexual arousal disorder, was published in the August 2008 issue of The Journal of Sexual Medicine. The article, entitled, “Efficacy and Safety of Alprostadil Cream for the Treatment of Female Sexual Arousal Disorder: A Double-Blind, Placebo-Controlled Study in Chinese Population,” describes the results of NexMed’s 400 patient take-home study completed in China in 2005.
